Stocks
Immunome Financial Statements (IMNM) |
||||||||||
| Immunomesmart-lab.ru | % | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.11.2023 | 28.03.2024 | 14.05.2024 | 12.08.2024 | 13.11.2024 | 13.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 3.57 | 3.83 | 1.03 | 2.36 | 2.91 | 10.1 | |||
| Operating Income, bln rub | -4.63 | -94.7 | -132.3 | -40.0 | -50.5 | -317.5 | ||||
| EBITDA, bln rub | ? | -4.52 | -13.7 | -20.2 | -35.4 | -50.5 | -119.9 | |||
| Net profit, bln rub | ? | -4.35 | -92.6 | -129.5 | -36.1 | -47.1 | -305.3 | |||
| OCF, bln rub | ? | -8.61 | -17.5 | -11.2 | -23.4 | -34.2 | -86.2 | |||
| CAPEX, bln rub | ? | 0.036 | 0.349 | 2.16 | 2.34 | 1.54 | 6.40 | |||
| FCF, bln rub | ? | -8.65 | -17.8 | -13.3 | -25.7 | -35.7 | -92.6 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 8.20 | 98.2 | 133.1 | 41.7 | 53.4 | 326.4 | ||||
| Cost of production, bln rub | 0.166 | 0.257 | 0.263 | 0.673 | 0.000 | 1.19 | ||||
| R&D, bln rub | 3.82 | 90.2 | 127.1 | 29.1 | 6.71 | 253.0 | ||||
| Interest expenses, bln rub | 0.000 | 0.201 | 0.000 | 0.000 | 0.000 | 0.201 | ||||
| Assets, bln rub | 93.2 | 148.5 | 319.8 | 296.2 | 256.9 | 256.9 | ||||
| Net Assets, bln rub | ? | 6.08 | 119.9 | 285.6 | 253.8 | 214.9 | 214.9 | |||
| Debt, bln rub | 0.371 | 1.65 | 1.63 | 2.77 | 2.46 | 2.46 | ||||
| Cash, bln rub | 90.6 | 138.1 | 309.7 | 278.4 | 240.1 | 240.1 | ||||
| Net debt, bln rub | -90.3 | -136.5 | -308.1 | -275.6 | -237.7 | -237.7 | ||||
| Ordinary share price, rub | 8.35 | 10.7 | 24.7 | 12.1 | 14.6 | 2.50 | ||||
| Number of ordinary shares, mln | 12.2 | 22.0 | 10.3 | 59.9 | 60.2 | 60.2 | ||||
| Market cap, bln rub | 102 | 235 | 254 | 725 | 880 | 151 | ||||
| EV, bln rub | ? | 12 | 98 | -54 | 450 | 643 | -87 | |||
| Book value, bln rub | 6 | 120 | 286 | 254 | 215 | 215 | ||||
| EPS, rub | ? | -0.36 | -4.22 | -12.6 | -0.60 | -0.78 | -5.07 | |||
| FCF/share, rub | -0.71 | -0.81 | -1.29 | -0.43 | -0.59 | -1.54 | ||||
| BV/share, rub | 0.50 | 5.46 | 27.7 | 4.24 | 3.57 | 3.57 | ||||
| EBITDA margin, % | ? | -126.8% | -358.1% | -1 962% | -1 500% | -1 736% | -1 183% | |||
| Net margin, % | ? | -121.9% | -2 421% | -12 584% | -1 528% | -1 619% | -3 015% | |||
| FCF yield, % | ? | 2.60% | -3.58% | -18.0% | -9.04% | -10.5% | -61.5% | |||
| ROE, % | ? | -368.3% | -88.9% | -81.3% | -103.4% | -142.1% | -142.1% | |||
| ROA, % | ? | -24.0% | -71.8% | -72.6% | -88.6% | -118.9% | -118.9% | |||
| P/E | ? | -4.55 | -2.20 | -1.10 | -2.76 | -2.88 | -0.49 | |||
| P/FCF | 38.4 | -28.0 | -5.56 | -11.1 | -9.51 | -1.63 | ||||
| P/S | ? | 10.00 | 16.8 | 20.1 | 67.3 | 86.9 | 14.9 | |||
| P/BV | ? | 16.8 | 1.96 | 0.89 | 2.86 | 4.10 | 0.70 | |||
| EV/EBITDA | ? | -0.52 | -3.48 | 1.22 | -6.09 | -5.36 | 0.73 | |||
| Debt/EBITDA | 4.08 | 4.82 | 7.00 | 3.73 | 1.98 | 1.98 | ||||
| R&D/CAPEX, % | 10 619% | 25 840% | 5 872% | 1 241% | 435.7% | 3 956% | ||||
| CAPEX/Revenue, % | 1.01% | 9.12% | 210.3% | 99.2% | 52.9% | 63.1% | ||||
| Immunome shareholders | ||||||||||
